Ebola vaccines protect people from contracting the Ebola virus disease (EVD), a viral hemorrhagic fever caused by ebolaviruses. Ebola vaccines include replication-deficient adenovirus vectors, replication-competent vesicular stomatitis (VSV), human parainfluenza (HPIV-3) vectors, and virus-like nanoparticle preparations.
Ervebo (rVSVΔG-ZEBOV-GP) is a recombinant, replication-competent Ebola vaccine.
Zabdeno and Mvabea Ebola vaccine therapy is a prime-boost vaccination approach used during Ebola outbreaks for individuals at risk of exposure and preventively, before outbreaks, for national and international first responders.
Ad5-EBOV is an adenovirus type 5 vector-based Ebola virus disease vaccine.
Ebanga (mAb114) is a human monoclonal antibody treatment.
Note: Content Sources for this page include the World Health Organization, the US Centers for Disease Control and Prevention, clinicaltrials.gov, and the Precision Vaccinations news network. Dr. Robert Carlson has reviewed this information.